イミックス・バイオファーマに関するコメント

$イミックス・バイオファーマ(IMMX.US)$
NEWS
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
Immix Biopharma, Inc. has been granted European Orphan Drug Designation for NXC-201 in the treatment of multiple myeloma, providing 10 years of market exclusivity, access to centralized authorization procedure, and reduced fees for various applications. The Company aims to address unmet medical needs in frail patients with relapsed/refractory multiple myeloma, with poten...

$イミックス・バイオファーマ(IMMX.US)$ Immix Biopharma on Track to Dose First Patients With AL Amyloidosis Therapy by Mid-Year
MT Newswires· 1 min ago
Immix Biopharma (IMMX) Thursday said it is on track to dose first patients with relapsed or refractory AL Amyloidosis with its CAR-T NXC-201 therapy candidate by mid-2024 after scheduling initiation visits at US testing locations this month and May.
The open-label, phase 1b dose-expansion trial is expected to enroll around 40 patients with adequate cardia...

$イミックス・バイオファーマ(IMMX.US)$
NEWS
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
LOS ANGELES, April 15, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced that updated...

$イミックス・バイオファーマ(IMMX.US)$ Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

$イミックス・バイオファーマ(IMMX.US)$ Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
5 MINUTES AGO, 4:45 PM EST
VIA GLOBENEWSWIRE

$イミックス・バイオファーマ(IMMX.US)$
LOS ANGELES, February 5, 2024 — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that it has priced an underwritten public offering of 5,535,055 shares of its common stock at an offering price of $2.71 per share of common stock. ImmixBio has granted the underwriters a 30-day option to purchase up to 783,970 additional sha...

$イミックス・バイオファーマ(IMMX.US)$  At support. Should move from 2.77 to 4.77 by the end of the month before another pullback.

$イミックス・バイオファーマ(IMMX.US)$ Immix Biopharma Announces FDA Approval Of IND Application For CAR-T NXC-201, Enabling U.S. Patient Dosing
Benzinga· 2 mins ago

$イミックス・バイオファーマ(IMMX.US)$ Immix Biopharma Presents NXC-201 Data At 65th American Society Of Hematology Annual Meeting In 9 Relapsed/Refractory AL Amyloidosis Patients
Benzinga· 4 mins ago
100% overall response rate observed in relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapy
Updated results will be communicated at the presentation time December 10, 2023

$イミックス・バイオファーマ(IMMX.US)$ WHY ME IMMX TODAY 🤔